At Edgewise, we know that patients are at the core of everything we do. As we develop our science and potential treatments, Edgewise’s promise to patients is to:
- put the best interest of patients first
- work with uncompromising standards in all we do
- listen to the communities that we work in and be transparent in our communications
- recognize that for rare disease patients, every day is a day too late and work with a sense of urgency.
Want to get in touch? Please contact firstname.lastname@example.org.
Edgewise is currently focusing on the dystrophinopathies, Duchenne and Becker muscular dystrophy, certain forms of Limb girdle muscular Dystrophy and other adult skeletal muscle diseases. Learn more about these diseases.
The clinical trial process is an important aspect of bringing a new therapy to patients. It tests whether the potential treatment is safe and effective for the intended population. Each trial is designed to answer a different question and inform the next trial. For more information about the clinical trial process:
Active Clinical Trials
A Study to Assess Safety, Tolerability, and PK of EDG-5506 in Healthy Volunteers and Becker Muscular Dystrophy Adults
EDG-5506 is an investigational product intended to protect and improve function of dystrophic muscle fibers. This Phase 1 study of EDG-5506 will assess the safety, tolerability, and pharmacokinetics (PK) and of EDG-5506 in adult healthy volunteers and in adults with Becker muscular dystrophy (BMD).
For more information about this trial, please contact, email@example.com
Community & Resources
Edgewise is proud to partner with the patient advocacy communities we work in. We work actively with our partners on initiatives that accelerate the development of meaningful treatments and impact the lives of patients. Click on a logo to learn more about our partners.